Revenue, last quarter
$690.1M
+13.3% vs same quarter last year
Net income
$144.7M
−49.1% vs same quarter last year
EPS, diluted
$0.32
−51.5% vs same quarter last year
Operating cash flow
$686.1M
−2.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $2.4B | $770.9M |
| FY24 | $2.3B | $859M |
| FY23 | $2.4B | $1.1B |
| FY22 | $2.2B | $42.8M |
| FY21 | $2.3B | $619.7M |
| FY20 | $2.1B | $975M |
| FY19 | $1.8B | $2.3B |
| FY18 | $1.8B | $1.4B |
| FY17 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | 65.6% | 32.4% |
| FY24 | 57.1% | 37.9% |
| FY23 | 63.4% | 48.2% |
| FY22 | 13.7% | 1.9% |
| FY21 | 62.5% | 27.1% |
| FY20 | 75.2% | 45.9% |
| FY19 | 144.6% | 129.4% |
| FY18 | 76% | 76.8% |
| FY17 | - | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $1.2B |
| FY24 | $229.7M |
| FY23 | $304.8M |
| FY22 | $0 |
| FY21 | $0 |
| FY20 | $0 |
| FY19 | $4.3M |
| FY18 | $0 |
| FY17 | - |
- Royalty Pharma
- Healthcare median
Show the numbers
| Year | Royalty Pharma | Healthcare median |
|---|---|---|
| FY25 | 32.4% | −30.6% |
| FY24 | 37.9% | −47% |
| FY23 | 48.2% | −58% |
| FY22 | 1.9% | −80.4% |
| FY21 | 27.1% | −71.9% |
| FY20 | 45.9% | −62.2% |
| FY19 | 129.4% | −46.3% |
| FY18 | 76.8% | −49.6% |
| FY17 | - | −45.9% |